India’s pharmaceutical industry is on the brink of an extraordinary growth trajectory, with exports expected to increase significantly, aiming for Rs. 30,76,500 crore (US$ 350 billion) by 2047, marking a 10-15 times growth from current levels. This surge is part of India’s ambitious plan to build on its already dominant position as a global leader in the generic drug market, while expanding into higher-value segments such as specialty generics, biosimilars, and innovative pharmaceutical products.

According to a report by Bain & Company, India’s pharmaceutical exports are projected to grow from approximately Rs. 2,37,330 crore (US$ 27 billion) in 2023 to Rs. 5,71,350 crore (US$ 65 billion) by 2030, with the ultimate target being a 10x increase to reach Rs. 30,76,500 crore (US$ 350 billion) by 2047. This exponential growth will be driven by a shift from a volume-based to a value-driven strategy, focusing on Active Pharmaceutical Ingredients (APIs), biosimilars, and generic formulations.

Focus Areas for Growth

APIs, a key component of pharmaceutical exports, are expected to experience substantial growth, with projections showing a rise from Rs. 43,950 crore (US$ 5 billion) in 2023 to Rs. 7,03,200 – 7,91,100 crore (US$ 80-90 billion) by 2047. This growth is attributed to India’s capacity to supply high-quality APIs that are crucial for generic drug formulations globally.

Biosimilars, another critical area, are expected to see a fivefold increase in exports, with projections ranging between Rs. 2,63,700 – 3,07,650 crore (US$ 30-35 billion) by 2047. India’s growing expertise in biosimilars, especially in the manufacturing of biologic medicines, positions it as a leader in this sector.

Generic formulations, the largest component of India’s pharmaceutical exports, will continue to grow robustly, reaching between Rs. 15,82,200 – 16,70,100 crore (US$ 180-190 billion) by 2047. India is already the world’s largest supplier of generic drugs, and this growth will be fueled by a greater focus on specialty generics, which are more complex and offer higher profit margins.

Policy Measures and Strategic Collaborations

To sustain this growth, the Bain & Company report emphasizes the importance of targeted policy measures, increased research and development (R&D), and strengthened collaboration between the government and the private sector. These measures will be essential to fostering innovation, improving manufacturing capabilities, and expanding global market access.

One of the critical contributors to India’s pharmaceutical growth will be its investments in contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). These entities provide outsourced services to global pharmaceutical companies, enabling India to tap into international demand while enhancing its pharmaceutical manufacturing capacity.

India’s pharmaceutical sector is well-placed to benefit from global market trends, including an increasing demand for affordable healthcare and generic drugs, as well as a growing shift towards biological medicines. With the right policy and investment strategies, India’s pharmaceutical industry can not only meet but exceed its ambitious export goals.

As the pharmaceutical sector continues to evolve, India will become a hub for innovation and value-added pharmaceutical products, reinforcing its global leadership in the generic drug supply chain and biosimilars market.

The Upcoming IPOs in this week and coming weeks are PS Raj Steels, Chandan Healthcare, Ajax Engineering, Voler Car, Maxvolt Energy, Hexaware Technologies, L.K. Mehta, Shanmuga Hospital.

The Current active IPO are Eleganz Interiors, Readymix Construction, Solarium Green.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.